[Systemic adjuvant chemotherapy of bladder carcinoma with 5 fluorouracil and cyclophosphamide]

Minerva Urol Nefrol. 1991 Oct-Dec;43(4):273-7.
[Article in Italian]

Abstract

Patients with bladder cancer in pT2 and pT3 infiltrating stages have a 5 year survival rate less than 50% after primary surgical and/or radiant therapy. Aim of the present study was to evaluate if adjuvant chemotherapy could improve survival in these subjects. For this purpose, 16 patients underwent treatment with 5-Fluorouracil and cyclophosphamide (min. three, max six courses). The obtained results have shown a 5 year actuarial survival rate of about 48%. Our experience has not shown therefore any improvement compared with primary treatment alone.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Chemotherapy, Adjuvant
  • Cyclophosphamide / therapeutic use*
  • Female
  • Fluorouracil / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Remission Induction
  • Survival Rate
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / surgery

Substances

  • Cyclophosphamide
  • Fluorouracil